Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC.
Packaging small drug molecules, such as non-steroidal anti-inflammatory drugs (NSAIDs) into nanoparticulate systems has been reported as a promising approach to improve the drug's bioavailability, biocompatibility and safety profiles. In the last 20 years, lipid nanoparticles (lipid dispersions) entered the nanoparticulate library as novel carrier systems due to their great potential as an alternative to other systems such as polymeric nanoparticles and liposomes for several administration routes. For ocular instillation nanoparticulate carriers are required to have a low mean particle size, with the lowest polydispersity as possible. The purpose of this work was to study the combined influence of 2-level, 4-factor variables on the formulation of flurbiprofen (FB), a lipophilic NSAID, in lipid carriers currently named as nanostructured lipid carriers (NLC). NLC were produced with stearic acid (SA) and castor oil (CO) stabilized by Tween® 80 (non-ionic surfactant) in aqueous dispersion. A 2(4) full factorial design based on 4 independent variables was used to plan the experiments, namely, the percentage of SA with regard to the total lipid, the FB concentration, the stabilizer concentration, and the storage conditions (i.e., storage temperature). The effects of these parameters on the mean particle size, polydispersity index (PI) and zeta potential (ZP) were investigated as dependent variables. The optimization process was achieved and the best formulation corresponded to the NLC formulation composed of 0.05 (wt%) FB, 1.6 (wt%) Tween® 80 and a 50:50 ratio of SA to CO, with an average diameter of 288 nm, PI 0.245 of and ZP of -29 mV. This factorial design study has proven to be a useful tool in optimizing FB-loaded NLC formulations. Stability of the optimized NLC was predicted using a TurbiScanLab® and the ocular tolerance was assessed in vitro and in vivo by the Eytex® and Draize test, respectively. The developed systems were shown physico-chemically stable with high tolerance for eye instillation.
Gonzalez-Mira
E
E
Department of Physical Chemistry, Faculty of Pharmacy, Institute of Nanoscience and Nanotechnology, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain.
Egea
M A
MA
Garcia
M L
ML
Souto
E B
EB
D000826:Animal Testing Alternatives / Q000379:methods; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity; D002368:Castor Oil / Q000737:chemistry; D004337:Drug Carriers / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000737:chemistry / Q000633:toxicity*; D015195:Drug Design; D004355:Drug Stability; D004361:Drug Tolerance; D005123:Eye / Q000187:drug effects*; D005480:Flurbiprofen / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity*; D007509:Irritants / Q000008:administration & dosage / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry* / Q000633:toxicity; D010316:Particle Size; D011136:Polysorbates / Q000737:chemistry; D011237:Predictive Value of Tests; D011817:Rabbits; D023422:Skin Irritancy Tests / Q000379:methods; D013229:Stearic Acids / Q000737:chemistry; D013499:Surface Properties; D023822:Tissue Engineering; D014465:Ultrasonics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D007509:Irritants; D011136:Polysorbates; D013229:Stearic Acids; C031183:stearic acid; D005480:Flurbiprofen; D002368:Castor Oil